Nuclear Data Sheets for A=64

Singh, Balraj; Chen, J.

doi:10.1016/j.nds.2021.11.002

Cited by 11 publications

(3 citation statements)

References 655 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decay data have conventionally received more attention with regard to their standardisation, and detailed evaluated mass decay chains are available for the above-mentioned five radionuclides (Junde et al, 2005;Nichols et al, 2012;Browne and Tuli, 2013;Zuber and Singh, 2015;Singh and Chen, 2021). The data given in Table 1 are all standardised, especially the halflives, the γ-ray energies and their intensities, as well as the β + (β -) energies and their intensities.…”

Section: Standardised Decay Data: Discrepancies and Deficienciesmentioning

confidence: 99%

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Hussain,

Qaim,

Spahn

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules. This characteristic makes it suitable for applications in molecular imaging or radionuclide targeted therapy. Of particular interest in nuclear medicine today is the theranostic approach. This brief review considers five radionuclides of copper. These are Cu-60, Cu-61, Cu-62, Cu-64, and Cu-67. The first four are positron emitters for imaging, and the last one Cu-67 is a β–-emitting radionuclide suitable for targeted therapy. The emphasis here is on theory-aided evaluation of available experimental data with a view to establishing standardised cross-section database for production of the relevant radionuclide in high purity. Evaluated cross section data of the positron emitters have been already extensively reported; so here they are only briefly reviewed. More attention is given to the data of the 68Zn(p,2p)67Cu intermediate energy reaction which is rather commonly used for production of 67Cu.

show abstract

Section: Standardised Decay Data: Discrepancies and Deficienciesmentioning

confidence: 99%

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Hussain,

Qaim,

Spahn

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…This radioisotope presents a complex decay scheme, which includes electron capture, beta minus, and positron emissions. The low-energy positrons emitted (17.49%, max 0.653 MeV, mean 0.278 MeV) are excellent for positron emission tomography imaging, especially due to a spatial resolution similar to fluorine-18, as determined by comparable average free travel distance of positrons (0.70 mm in the case of copper-64 and 0.69 mm in the case of fluorine-18) [ 1 , 2 ]. The lack of abundant gamma emissions (only 0.47%, 1.346 MeV) is also an advantage since they can cause interferences that impact the image quality, as in the case of other non-pure positron emitters such as bromine-76, yttrium-86, rubidium-82, and iodine-124 [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…The β − emission (38.48%, max 0.579 MeV, mean 0.190 MeV) offers the possibility for targeted radionuclide therapy with a highly localised dose, in situ visualised by the means of β + (PET). Additionally, the electron capture events determine the emission of Auger electrons (Auger L 0.84 keV, 58.0% and Auger K 6.54 keV, 22.62%) which increases the radiotoxicity of the radioisotope when delivered inside the targeted cells, in particular when the emitting radioisotope is trapped in the cell nucleus [ 1 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Neurotensin (8-13) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets

Cocioabă,

Fonseca,

Leonte

et al. 2024

Molecules

View full text Add to dashboard Cite

On the verge of a theranostic approach to personalised medicine, copper-64 is one of the emerging radioisotopes in nuclear medicine due to its exploitable nuclear and biochemical characteristics. The increased demand for copper-64 for preclinical and clinical studies has prompted the development of production routes. This research aims to compare the (p,n) reaction on nickel-64 solid versus liquid targets and evaluate the effectiveness of [64Cu]CuCl2 solutions prepared by the two routes. As new treatments for neurotensin receptor-overexpressing tumours have developed, copper-64 was used to radiolabel Neurotensin (8-13) and Neuromedin N. High-quality [64Cu]CuCl2 solutions were prepared using ACSI TR-19 and IBA Cyclone Kiube cyclotrons. The radiochemical purity after post-irradiation processing reached 99% (LT) and 99.99% (ST), respectively. The irradiation of a solid target with 11.8 MeV protons and 150 μAh led to 704 ± 84 MBq/μA (17.6 ± 2.1 GBq/batch at EOB). At the end of the purification process (1 h, 90.90% activity yield), the solution for peptide radiolabelling had a radioactive concentration of 1340.4 ± 70.1 MBq/mL (n.d.c.). The irradiation of a liquid target with 16.9 MeV protons and 230 μAh resulted in 3.7 ± 0.2 GBq/batch at EOB, which corresponds to an experimental production yield of 6.89 GBq.cm3/(g.µA)sat. Benefiting from a shorter purification process (40 min), the activity yielded 90.87%, while the radioactive concentration of the radiolabelling solution was lower (492 MBq/mL, n.d.c.). The [64Cu]CuCl2 solutions were successfully used for the radiolabelling of DOTA-NT(8-13) and DOTA-NN neuropeptides, resulting in a high RCP (>99%) and high molar activity (27.2 and 26.4 GBq/μmol for LT route compared to 45 and 52 GBq/μmol for ST route, respectively). The strong interaction between the [64Cu]Cu-DOTA-NT(8-13) and the colon cancerous cell lines HT29 and HCT116 proved that the specificity for NTR had not been altered, as shown by the uptake and retention data.

show abstract

Nitrogen-13, oxygen-15 and carbon-11 in positron emission tomography: an overview

Petroni,

Menichetti

2024

J Radioanal Nucl Chem

View full text Add to dashboard Cite

Nuclear Data Sheets for A=64

Cited by 11 publications

References 655 publications

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Neurotensin (8-13) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets

Nitrogen-13, oxygen-15 and carbon-11 in positron emission tomography: an overview

Contact Info

Product

Resources

About